Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences

on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team

doi:10.5230/jgc.2024.24.e40

Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences

on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team

Department of Internal Medicine

National Cancer Center Korea
Chungbuk National University

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	353-355
Number of pages	3
Journal	Journal of Gastric Cancer
Volume	24
Issue number	4
DOIs	https://doi.org/10.5230/jgc.2024.24.e40
State	Published - Oct 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.5230/jgc.2024.24.e40

Cite this

on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team (2024). Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences. Journal of Gastric Cancer, 24(4), 353-355. https://doi.org/10.5230/jgc.2024.24.e40

on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team. / Reply : Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences. In: Journal of Gastric Cancer. 2024 ; Vol. 24, No. 4. pp. 353-355.

@article{e4718e7d1ce94663aad2f1b258db0deb,

title = "Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences",

author = "\{on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team\} and Kim, \{In Ho\} and Wonyoung Choi and Han, \{Hye Sook\}",

year = "2024",

month = oct,

doi = "10.5230/jgc.2024.24.e40",

language = "English",

volume = "24",

pages = "353--355",

journal = "Journal of Gastric Cancer",

issn = "2093-582X",

publisher = "Korean Gastric Cancer Association",

number = "4",

}

on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team 2024, 'Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences', Journal of Gastric Cancer, vol. 24, no. 4, pp. 353-355. https://doi.org/10.5230/jgc.2024.24.e40

Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences. / on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team.
In: Journal of Gastric Cancer, Vol. 24, No. 4, 10.2024, p. 353-355.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply

T2 - Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences

AU - on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team

AU - Kim, In Ho

AU - Choi, Wonyoung

AU - Han, Hye Sook

PY - 2024/10

Y1 - 2024/10

UR - https://www.scopus.com/pages/publications/85206921948

U2 - 10.5230/jgc.2024.24.e40

DO - 10.5230/jgc.2024.24.e40

M3 - Letter

AN - SCOPUS:85206921948

SN - 2093-582X

VL - 24

SP - 353

EP - 355

JO - Journal of Gastric Cancer

JF - Journal of Gastric Cancer

IS - 4

ER -

on behalf of The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team. Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences. Journal of Gastric Cancer. 2024 Oct;24(4):353-355. doi: 10.5230/jgc.2024.24.e40

Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H GastriCancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences

UN SDGs

Access to Document

Other files and links

Cite this